Drug Resistance
Structure-based phenotyping predicts HIV-1 protease inhibitor resistance
Published in Medical Letter on the CDC and FDA, September 21st, 2003
"Mutations in HIV-1 drug targets lead to resistance and consequent therapeutic failure of antiretroviral drugs. Phenotypic resistance assays are time-consuming and costly, and genotypic rules-based interpretations may fail to predict the effects of multiple mutations. We have developed a computational procedure that rapidly evaluates changes in the binding energy of inhibitors to mutant HIV-1 PR variants," scientists in the United States report.
"Models of WT complexes were produced from crystal structures," said Mark D. Shenderovich and collaborators at Cengent Therapeutics...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- HIV/AIDS Diagnosis
Whole-blood agglutination assay allows on-site detection of HIV infection - Anthrax
Pathology and pathogenesis of inhalational anthrax reviewed - Antimicrobial Resistance
Program controls vancomycin-resistant Enterococcus among inpatients - Poliovirus
Endemic type 2 vaccine-derived poliovirus found in Egypt from 1983 to 1993 - Vaccinology
Standards for adult immunization practices revised - Adverse Drug Reactions
Capecitabine induces pancreatitis in breast cancer patient - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
